Answers are grounded in this paper and cite their sources.
An abnormality in the interaction of 1,25-dihydroxyvitamin D [1,25-(OH)2D] with its specific intracellular receptor has been postulated to explain the resistance of patients with X-linked hypophosphatemia (XLH) to treatment with vitamin D. To investigate this possibility, the specific internalization of [3H]1,25-(OH)2D3 by suspensions of cultured dermal fibroblasts from six patients with XLH was evaluated. Scatchard analysis of the specific uptake of [3H]1,25-(OH)2D3 by intact XLH fibroblasts revealed a mean internalization constant (Kin) of 0.72 +/- 0.10 nM (mean +/- SE) and a cellular capacity for hormone (Nmax) of 61.5 +/- 5.4 fmol/mg protein. The Kin and Nmax for XLH cells were similar to the mean values obtained for normal fibroblasts (0.59 nM and 72 fmol/mg protein, respectively) and cells from a patient with acquired hypophosphatemia (0.67 nM and 73 fmol/mg protein, respectively). Conversely, cultured fibroblasts from a patient with vitamin D-dependent rickets type II demonstrated a marked reduction of sterol uptake when compared to that in cells from either a hypophosphatemic or normal host. Neither the affinity nor the capacity of XLH fibroblasts for [3H]1,25-(OH)2D3 was influenced by exposure of proliferating or confluent monolayer cultures to a low phosphate concentration (2.0 mg/dl) in the extracellular medium before or during assay. In addition, the normal responsiveness of cultured fibroblasts from three patients with XLH to 1,25-(OH)2D3 was confirmed by the provocative induction of the cellular 25-hydroxyvitamin D3-24-hydroxylase. These data suggest that 1,25-(OH)2-D3-receptor binding as well as postreceptor events are normal in patients with XLH.
No takes yet. Share an insight, caveat, or question.
Adams et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: